Coronary & Ischemic Heart DiseaseApril 27, 20267 min read

Everything You Need to Know About Atherosclerosis pathogenesis for Step 1

Deep dive: definition, pathophysiology, clinical presentation, diagnosis, treatment, HY associations for Atherosclerosis pathogenesis. Include First Aid cross-references.

Atherosclerosis is one of those Step 1 “small concept, huge consequences” topics: you can understand it in an afternoon, but it explains stable angina, MI, stroke, PAD, aneurysms, and a ton of pharmacology and pathology vignettes. If you can tell a clean story—endothelial injury → lipid entry/oxidation → inflammation → foam cells → smooth muscle migration → fibrous cap—you’ll crush most coronary/ischemic heart disease questions built on this foundation.


Where this fits (and why it’s Step 1 gold)

Atherosclerosis is a chronic, inflammatory disease of medium and large arteries driven by lipid accumulation and endothelial dysfunction, culminating in plaque formation and either:

  • Progressive luminal narrowing → predictable ischemia (e.g., stable angina)
  • Acute plaque disruption with thrombosis → infarction (e.g., MI, stroke)

First Aid cross-reference (general):

  • Pathology → Atherosclerosis
  • Cardiovascular → Ischemic heart disease/MI, Angina
  • Pharm → Statins, antiplatelets, antihypertensives

Definition (use the buzzwords)

Atherosclerosis = intimal thickening with:

  • Lipid core (cholesterol, foam cells, necrotic debris)
  • Fibrous cap (smooth muscle cells + collagen)
  • Chronic inflammation (macrophages, T cells)

Key distinction: This is a type of arteriosclerosis (hardening of arteries). Other “-sclerosis” entities you must not confuse:

  • Arteriolosclerosis (hyaline/hyperplastic) → HTN/DM, small vessels
  • Monckeberg medial calcific sclerosis → calcified media, usually benign

Pathogenesis: the Step 1 “movie plot”

You’ll see questions that give risk factors + a plaque complication and ask “what’s happening at the cellular level?” Here’s the high-yield sequence.

1) Endothelial injury/dysfunction (the trigger)

Common causes:

  • Hypertension (shear stress)
  • Hyperlipidemia (especially ↑ LDL)
  • Cigarette smoking
  • Diabetes mellitus
  • Inflammation (e.g., elevated CRP), toxins, homocystinuria (less common but tested)

What dysfunctional endothelium does:

  • ↑ permeability to lipoproteins
  • ↑ leukocyte adhesion (VCAM-1 etc.)
  • ↓ NO (less vasodilation, more platelet aggregation)
  • Pro-thrombotic state (less antithrombotic signaling)

HY vignette clue: long-standing HTN + smoker + high LDL → “endothelial dysfunction with increased permeability to lipoproteins.”

2) LDL enters the intima and becomes oxidized

  • LDL migrates into the intima and gets oxidized.
  • Oxidized LDL is pro-inflammatory and chemoattractant.

Why oxidized LDL matters (testable):

  • Promotes macrophage uptake via scavenger receptors (unregulated)
  • Stimulates cytokines → more inflammation
  • Toxic to endothelium → worsens dysfunction

3) Monocytes adhere → become macrophages → foam cells

  • Monocytes migrate into intima → macrophages.
  • Macrophages ingest oxidized LDL → foam cells.
  • Foam cells aggregate → fatty streaks.

Fatty streaks

  • Earliest visible lesion
  • Can be seen in youth
  • May progress to plaques (especially with risk factors)

4) Smooth muscle migration + proliferation + ECM deposition

  • Smooth muscle cells migrate from media → intima (stimulated by growth factors like PDGF).
  • They proliferate and secrete collagen + extracellular matrix → builds the fibrous cap.

Core Step 1 point: plaques are not just “fat”; they are active inflammatory lesions with smooth muscle and collagen.

5) Mature atheromatous plaque

Final structure:

  • Fibrous cap (collagen + SMC)
  • Necrotic lipid core (cholesterol, foam cells, debris)
  • “Shoulder” region with inflammatory cells (often the weak point)

Stable vs vulnerable plaques (how Step questions trick you)

Not all plaques behave the same.

FeatureStable plaqueVulnerable (unstable) plaque
Fibrous capThickThin
Lipid coreSmallerLarge
InflammationLessMore macrophages/T cells
Main consequenceChronic luminal narrowing → stable anginaRupture/erosion → thrombosis → MI/unstable angina
Clinical patternPredictable exertional symptomsOften at rest, acute events

HY punchline: The plaque that causes an acute MI is often not the biggest stenosis—it’s the most rupture-prone.


Complications (very testable)

Atherosclerosis causes problems via stenosis or plaque change.

1) Progressive stenosis → chronic ischemia

  • Stable angina (exertional chest pain relieved by rest/nitro)
  • Chronic mesenteric ischemia (“intestinal angina”)
  • Peripheral artery disease (claudication)

2) Plaque rupture/erosion → thrombosis → infarction

  • MI (coronary thrombosis)
  • Ischemic stroke (carotid plaque rupture/embolization)
  • Acute limb ischemia

Mechanism: exposed subendothelial collagen + tissue factor → platelet activation and coagulation.

3) Cholesterol embolization

  • Plaque debris showers downstream, often after vascular procedures.
  • Can cause livedo reticularis, “blue toe,” AKI.

4) Aneurysm formation (especially abdominal aorta)

  • Atherosclerosis weakens vessel wall (ischemia of media) → AAA
  • Classic association: smoking, male, older age

First Aid tie-in: AAA and atherosclerosis are frequent neighbors in FA cardiovascular pathology sections.


Atherosclerosis is the upstream disease that sets the stage for the big coronary syndromes.

Stable angina (demand ischemia)

  • Fixed stenosis (often >70%) limits flow during exertion.
  • Subendocardium is most vulnerable (highest wall stress, farthest from epicardial vessels).

Acute coronary syndrome (ACS)

Triggered by plaque disruption:

  • Unstable angina: ischemia at rest; no troponin rise
  • NSTEMI: subendocardial infarct; troponins up, ST depression/T inversion
  • STEMI: transmural infarct; ST elevation, Q waves later

High-yield mechanistic link: ACS = thrombus on disrupted plaque, not simply “a plaque got bigger overnight.”


Risk factors (know the categories)

Non-modifiable

  • Age
  • Male sex (risk rises in women after menopause)
  • Family history/genetics

Modifiable (HY)

  • Hyperlipidemia (↑ LDL, ↓ HDL)
  • Hypertension
  • Smoking
  • Diabetes mellitus
  • Obesity, sedentary lifestyle

Lipid pearls that show up in vignettes

  • LDL = atherogenic (delivers cholesterol to tissues)
  • HDL = protective (reverse cholesterol transport)
  • Familial hypercholesterolemia (LDL receptor/ApoB-100 issues) → early CAD, tendon xanthomas

Diagnosis (what do you actually “see”?)

Atherosclerosis itself is often silent until it causes ischemia. Diagnosis focuses on:

  • Risk assessment: lipids, diabetes screening, BP, smoking history
  • Evidence of ischemia: ECG changes, stress testing, troponins in ACS
  • Anatomic assessment (when indicated): coronary CTA, angiography

Pathology gross description (Step-style):

  • Raised, yellow-white intimal plaques
  • Complicated lesions may show hemorrhage, ulceration, superimposed thrombus, calcification

Treatment: prevention + plaque stabilization + thrombosis prevention

Think in 3 lanes: risk factor modification, lipid lowering, antithrombotic therapy.

1) Lifestyle (always correct, often “best next step”)

  • Smoking cessation
  • Diet changes (lower saturated/trans fats)
  • Exercise and weight loss
  • Diabetes control, BP control

2) Statins (core pharmacology tie-in)

Mechanism: inhibit HMG-CoA reductase → ↓ cholesterol synthesis → ↑ LDL receptor expression → ↓ LDL

Why Step exams love statins in atherosclerosis:

  • Lower LDL and reduce cardiovascular events
  • Plaque “stabilization” concept (reduced inflammation, improved endothelial function—clinically meaningful even if simplified for Step)

Classic adverse effects: myopathy, ↑ LFTs (and rare rhabdo risk, higher with fibrates/niacin interactions)

3) Antiplatelets (especially secondary prevention)

  • Aspirin (COX inhibition → ↓ TXA2)
  • P2Y12 inhibitors (e.g., clopidogrel) in ACS/post-stent contexts

4) BP and diabetes management

  • Reduces endothelial injury and progression

5) Acute plaque rupture/ACS management (big picture)

  • Antiplatelets + anticoagulation + reperfusion strategy when indicated (PCI/thrombolysis for STEMI)

(You’ll cover detailed ACS algorithms elsewhere—here the key is that the acute event is thrombosis on a disrupted plaque.)


High-yield associations & “classic vignette” tells

Pathogenesis buzzwords to recognize

  • Endothelial dysfunction” + “oxidized LDL” + “foam cells
  • Fatty streak” in a young person (early lesion)
  • Thin fibrous cap with large lipid core” → rupture-prone plaque
  • Superimposed thrombus” → acute coronary syndrome

Common boards-style pairings

  • Smoking → AAA and worsening atherosclerosis
  • DM → accelerated atherosclerosis, often multi-vessel CAD
  • HTN → endothelial injury and plaque progression
  • Familial hypercholesterolemia → early MI, tendon xanthomas, corneal arcus

Frequently confused concepts (quick clarifiers)

  • Atherosclerosis is intimal and lipid-driven; hyaline arteriolosclerosis is small-vessel thickening from HTN/DM.
  • Stable angina is fixed stenosis; unstable angina/MI is plaque disruption + thrombosis.

Rapid review table (Step 1 speed mode)

ConceptMust-know takeaway
Initiating eventEndothelial injury/dysfunction (HTN, smoking, DM, hyperlipidemia)
Early lesionFatty streak = foam cells in intima
Key inflammatory stepOxidized LDL → macrophage uptake via scavenger receptors
Growth stepSMC migration/proliferation + collagen → fibrous cap
Stable plaqueThick cap → chronic narrowing → stable angina
Vulnerable plaqueThin cap, big lipid core → rupture → thrombosis → MI
Major complicationsStenosis, thrombosis, embolization, aneurysm

Final Step 1 takeaway (the one-sentence story)

Atherosclerosis is a chronic inflammatory response to endothelial injury where LDL enters and oxidizes, macrophages become foam cells, smooth muscle lays down a fibrous cap, and the clinical disaster happens when a vulnerable plaque ruptures and triggers thrombosis—especially in the coronaries.